With $45M in Funding, Startup Voyager Therapeutics Aims to Develop Expressed RNAi CNS Drugs | GenomeWeb

Venture capital firm Third Rock Ventures last week announced that it has put up $45 million to form a new company called Voyager Therapeutics to develop adeno-associated viral vector-enabled treatments for central nervous system disorders.

Although the company's lead program is a gene-replacement therapy for Parkinson's disease, Voyager has also set its sights on using its AAV technology to develop expressed RNAi drugs — an effort that includes a preclinical program in amyotrophic lateral sclerosis, according to a company executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.